| 000 | 01645 a2200469 4500 | ||
|---|---|---|---|
| 005 | 20250516212118.0 | ||
| 264 | 0 | _c20150409 | |
| 008 | 201504s 0 0 eng d | ||
| 022 | _a2219-2840 | ||
| 024 | 7 |
_a10.3748/wjg.v20.i17.5165 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aLiu, Wei-Ping | |
| 245 | 0 | 0 |
_aHepatitis B surface antigen seroconversion after HBV reactivation in non-Hodgkin's lymphoma. _h[electronic resource] |
| 260 |
_bWorld journal of gastroenterology _cMay 2014 |
||
| 300 |
_a5165-70 p. _bdigital |
||
| 500 | _aPublication Type: Case Reports; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal, Murine-Derived _xadverse effects |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xadverse effects |
| 650 | 0 | 4 |
_aAntiviral Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aBiomarkers _xblood |
| 650 | 0 | 4 |
_aDNA, Viral _xblood |
| 650 | 0 | 4 |
_aGuanine _xanalogs & derivatives |
| 650 | 0 | 4 |
_aHepatitis B _xblood |
| 650 | 0 | 4 |
_aHepatitis B Surface Antigens _xblood |
| 650 | 0 | 4 |
_aHepatitis B virus _xdrug effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLymphoma, Follicular _xdiagnosis |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aRituximab |
| 650 | 0 | 4 | _aTime Factors |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 | _aViral Load |
| 650 | 0 | 4 |
_aVirus Activation _xdrug effects |
| 700 | 1 | _aZheng, Wen | |
| 700 | 1 | _aSong, Yu-Qin | |
| 700 | 1 | _aPing, Ling-Yan | |
| 700 | 1 | _aWang, Gui-Qiang | |
| 700 | 1 | _aZhu, Jun | |
| 773 | 0 |
_tWorld journal of gastroenterology _gvol. 20 _gno. 17 _gp. 5165-70 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.3748/wjg.v20.i17.5165 _zAvailable from publisher's website |
| 999 |
_c23802926 _d23802926 |
||